A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of
SGN-75 in patients with CD70-positive relapsed or refractory non-Hodgkin lymphoma or
metastatic renal cell carcinoma.